| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.079 | 0.1 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.1 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.083 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.078 | 0.1 |